Trial intelligence / Profile preview

Cadonilimab plus Anlotinib Neoadjuvant Therapy for ESCC

NCT06426797Phase 2

Key facts

Status: Not yet recruiting
Start: May 2024
Primary completion: May 2025
Sponsor: Peking University People's Hospital
Modality: Bispecific Antibodies

Drugs: cadonilimab
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Overview

Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University People's Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start May 2024; status: not yet recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Cadonilimab + Anlotinib
Patients receive Cadonilimab and Anlotinib for 3 cycles followed by surgery.

Who it enrols

Patients with locally advanced resectable esophageal squamous cell carcinoma (T1-2N1-3M0, T2>=3cm N0M0, or T3-4aN0-3M0), ECOG 0-2, and adequate organ function. Excludes prior chemotherapy/radiotherapy for esophageal cancer, prior immune checkpoint inhibitors, active autoimmune disease, and severe cardiovascular conditions.

Endpoints

Primary

Pathological Complete Response Rate1 week after surgery

Secondary

Major Pathological Response Rate1 week after surgery
Objective Response Rate1 week before surgery
Treatment Emergent Adverse EventsUp to 24 months after participation
Event-free SurvivalUp to 24 months after participation

Beyond the preview

Go deeper on NCT06426797.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06426797.